Vyne Therapeutics has dosed the first participant in a randomised Phase Ib clinical trial of VYN202, an oral treatment for ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...

No new safety signals observed at Year 5 in the POETYK ... the first TYK2 inhibitor available for patients living with moderate-to-severe plaque psoriasis, as a potential oral standard of care.” ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Some of the most common reasons include: According to the World Health Organization (WHO), up to 4% of the world’s population experiences 15 or more headache days a month. If you are one of these ...

Current healthcare reforms have increased the demand for public health educators, health promotion specialists, and allied health professionals. The University of Houston’s Bachelor of Science Health ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial ... “These results further support the role of Sotyktu, the first TYK2 inhibitor available for patients living with ...

No new safety signals observed at Year 5 in the POETYK PSO long-term extension trial ... "These results further support the role of Sotyktu, the first TYK2 inhibitor available for patients living with ...